Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Gastroesophageal (GE) Junction Carcinomas-Pipeline Review, H1 2015

Gastroesophageal (GE) Junction Carcinomas-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Gastroesophageal (GE) Junction Carcinomas-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Gastroesophageal (GE) Junction Carcinomas-Pipeline Review, H1 2015', provides an overview of the Gastroesophageal (GE) Junction Carcinomas's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Gastroesophageal (GE) Junction Carcinomas and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Gastroesophageal (GE) Junction Carcinomas Overview 8

Therapeutics Development 9

Pipeline Products for Gastroesophageal (GE) Junction Carcinomas-Overview 9

Pipeline Products for Gastroesophageal (GE) Junction Carcinomas-Comparative Analysis 10

Gastroesophageal (GE) Junction Carcinomas-Therapeutics under Development by Companies 11

Gastroesophageal (GE) Junction Carcinomas-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Gastroesophageal (GE) Junction Carcinomas-Products under Development by Companies 15

Gastroesophageal (GE) Junction Carcinomas-Companies Involved in Therapeutics Development 16

Amgen Inc. 16

Aslan Pharmaceuticals Pte. Ltd. 17

AstraZeneca PLC 18

Basilea Pharmaceutica AG 19

Bristol-Myers Squibb Company 20

Celltrion, Inc. 21

Exelixis, Inc. 22

F. Hoffmann-La Roche Ltd. 23

Gilead Sciences, Inc. 24

Merck & Co., Inc. 25

Merck KGaA 26

Merrimack Pharmaceuticals, Inc. 27

Ono Pharmaceutical Co., Ltd. 28

Taiho Pharmaceutical Co., Ltd. 29

Gastroesophageal (GE) Junction Carcinomas-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

(tegafur + gimeracil + oteracil)-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

avelumab-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

BAL-101553-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

cabozantinib s-malate-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

DKN-01-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

gefitinib-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

GS-5745-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

ipilimumab-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

MK-2206-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

MM-111-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

nimotuzumab-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

nivolumab-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

pertuzumab-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

SNX-5422-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

trastuzumab biosimilar-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

trebananib-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

varlitinib-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Gastroesophageal (GE) Junction Carcinomas-Recent Pipeline Updates 82

Gastroesophageal (GE) Junction Carcinomas-Dormant Projects 115

Gastroesophageal (GE) Junction Carcinomas-Discontinued Products 116

Gastroesophageal (GE) Junction Carcinomas-Product Development Milestones 117

Featured News & Press Releases 117

Sep 19, 2014: Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on MM-111 at the ESMO 2014 Congress 117

Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University 117

Appendix 118

Methodology 118

Coverage 118

Secondary Research 118

Primary Research 118

Expert Panel Validation 118

Contact Us 118

Disclaimer 119

List of Tables

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H1 2015 9

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Amgen Inc., H1 2015 16

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 17

Gastroesophageal (GE) Junction Carcinomas-Pipeline by AstraZeneca PLC, H1 2015 18

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Basilea Pharmaceutica AG, H1 2015 19

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Bristol-Myers Squibb Company, H1 2015 20

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Celltrion, Inc., H1 2015 21

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Exelixis, Inc., H1 2015 22

Gastroesophageal (GE) Junction Carcinomas-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 23

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Gilead Sciences, Inc., H1 2015 24

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Merck & Co., Inc., H1 2015 25

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Merck KGaA, H1 2015 26

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 27

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 28

Gastroesophageal (GE) Junction Carcinomas-Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 29

Assessment by Monotherapy Products, H1 2015 30

Assessment by Combination Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Gastroesophageal (GE) Junction Carcinomas Therapeutics-Recent Pipeline Updates, H1 2015 82

Gastroesophageal (GE) Junction Carcinomas-Dormant Projects, H1 2015 115

Gastroesophageal (GE) Junction Carcinomas-Discontinued Products, H1 2015 116

List of Figures

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H1 2015 9

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 14

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Top 10 Targets, H1 2015 32

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Aslan Pharmaceuticals Pte. Ltd.

AstraZeneca PLC

Basilea Pharmaceutica AG

Bristol-Myers Squibb Company

Celltrion, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Ono Pharmaceutical Co., Ltd.

Taiho Pharmaceutical Co., Ltd.

Gastroesophageal (GE) Junction Carcinomas Therapeutic Products under Development, Key Players in Gastroesophageal (GE) Junction Carcinomas Therapeutics, Gastroesophageal (GE) Junction Carcinomas Pipeline Overview, Gastroesophageal (GE) Junction Carcinomas Pipeline, Gastroesophageal (GE) Junction Carcinomas Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com